BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on placental-derived biologics, has filed a Form 10 registration statement with the SEC on September 27, 2024. This marks a important step in the company's strategy to uplist to Nasdaq, reflecting its commitment to transparency and strong corporate governance. Once effective, BioStem will become a fully reporting company, enhancing its credibility and positioning for greater visibility and access to capital.
The company has also strengthened its compliance and reporting framework by completing two years of audited financial statements. CEO Jason Matuszewski emphasized that this move aligns with their strategic initiatives to enhance market visibility, financial transparency, and access to capital during a period of continued revenue growth. BioStem aims to drive revenue growth and market expansion for its products while pursuing its listing objectives.
BioStem Technologies, Inc. (OTC: BSEM), un'azienda leader nel settore MedTech focalizzata su biologici derivati dalla placenta, ha presentato un modulo di registrazione Form 10 alla SEC il 27 settembre 2024. Questo rappresenta un passo importante nella strategia dell'azienda per passare al Nasdaq, riflettendo il suo impegno verso la trasparenza e una solidità di governance aziendale. Una volta efficace, BioStem diventerà un'azienda a pieno titolo, migliorando la sua credibilità e posizionandosi per una maggiore visibilità e accesso al capitale.
L'azienda ha anche rafforzato il suo quadro di conformità e reporting completando due anni di bilanci finanziari auditati. Il CEO Jason Matuszewski ha sottolineato che questa mossa si allinea con le loro iniziative strategiche per migliorare la visibilità sul mercato, la trasparenza finanziaria e l'accesso al capitale durante un periodo di continua crescita dei ricavi. BioStem punta a promuovere la crescita dei ricavi e l'espansione del mercato per i suoi prodotti mentre persegue i suoi obiettivi di quotazione.
BioStem Technologies, Inc. (OTC: BSEM), una empresa líder en MedTech enfocada en biológicos derivados de la placenta, ha presentado una declaración de registro Form 10 a la SEC el 27 de septiembre de 2024. Esto marca un paso importante en la estrategia de la compañía para listar en Nasdaq, reflejando su compromiso con la transparencia y una sólida gobernanza corporativa. Una vez que sea efectiva, BioStem se convertirá en una empresa informante, mejorando su credibilidad y posicionándose para una mayor visibilidad y acceso a capital.
La empresa también ha fortalecido su marco de cumplimiento y reporting al completar dos años de estados financieros auditados. El CEO Jason Matuszewski enfatizó que este movimiento está alineado con sus iniciativas estratégicas para mejorar la visibilidad en el mercado, la transparencia financiera y el acceso a capital durante un período de crecimiento continuo de los ingresos. BioStem busca impulsar el crecimiento de ingresos y la expansión del mercado para sus productos mientras persigue sus objetivos de listado.
BioStem Technologies, Inc. (OTC: BSEM)은 태반에서 유래된 생물학적 제제에 중점을 둔 선도적인 MedTech 회사로서 2024년 9월 27일 SEC에 Form 10 등록 성명서를 제출했습니다. 이는 나스닥으로의 상장을 목표로 하는 회사의 전략에서 중요한 단계로, 투명성과 강력한 기업 거버넌스에 대한 그들의 헌신을 반영합니다. 효과가 발생하면 BioStem은 완전 고지 회사가 되어 신뢰성을 높이고 더 나은 가시성과 자본 접근을 위해 자리잡게 될 것입니다.
회사는 또한 규정 준수 및 보고 프레임워크를 강화하기 위해 두 년간의 감사 재무제표를 완료했습니다. CEO Jason Matuszewski는 이번 조치가 시장 가시성, 재무 투명성 및 자본 접근성을 향상시키기 위한 전략적 이니셔티브와 일치한다고 강조했습니다. BioStem은 제품의 수익 성장과 시장 확장을 촉진하면서 상장 목표를 추구하고자 합니다.
BioStem Technologies, Inc. (OTC: BSEM), une entreprise MedTech de premier plan axée sur les biologiques dérivés du placenta, a déposé une déclaration d'enregistrement Form 10 auprès de la SEC le 27 septembre 2024. Cela marque une étape importante dans la stratégie de l'entreprise pour s'inscrire au Nasdaq, reflétant son engagement envers la transparence et une gouvernance d'entreprise solide. Une fois effective, BioStem deviendra une entreprise à rapport complet, renforçant sa crédibilité et se positionnant pour une plus grande visibilité et un accès aux capitaux.
L'entreprise a également renforcé son cadre de conformité et de reporting en complétant deux années d'états financiers audités. Le PDG Jason Matuszewski a souligné que cette décision s'aligne avec leurs initiatives stratégiques pour améliorer la visibilité sur le marché, la transparence financière et l'accès aux capitaux pendant une période de croissance continue des revenus. BioStem vise à stimuler la croissance des revenus et l'expansion du marché pour ses produits tout en poursuivant ses objectifs d'inscription.
BioStem Technologies, Inc. (OTC: BSEM), ein führendes MedTech-Unternehmen, das sich auf placenta-abgeleitete Biologika konzentriert, hat am 27. September 2024 eine Formular 10-Registrierungsanmeldung bei der SEC eingereicht. Dies stellt einen wichtigen Schritt in der Strategie des Unternehmens dar, um an die Nasdaq aufzulisten, was das Engagement für Transparenz und starke Unternehmensführung widerspiegelt. Nach der Genehmigung wird BioStem ein vollberichterstattendes Unternehmen werden, was die Glaubwürdigkeit erhöht und das Unternehmen für mehr Sichtbarkeit und Zugang zu Kapital positioniert.
Das Unternehmen hat auch sein Einhaltung- und Berichtsrahmen gestärkt, indem es zwei Jahre geprüfter Finanzberichte abgeschlossen hat. CEO Jason Matuszewski betonte, dass dieser Schritt im Einklang mit ihren strategischen Initiativen steht, um die Marktübersicht, die finanzielle Transparenz und den Zugang zu Kapital in einer Phase des kontinuierlichen Umsatzwachstums zu verbessern. BioStem zielt darauf ab, das Umsatzwachstum und die Markterweiterung für seine Produkte zu fördern, während es seine Listungsziele verfolgt.
- Filed Form 10 registration statement with the SEC, a key step towards Nasdaq uplisting
- Completed two years of audited financial statements, strengthening compliance and reporting framework
- Pursuing Nasdaq listing to increase market visibility and global liquidity opportunities
- Experiencing continued revenue growth
- Uplisting to Nasdaq is contingent upon approval and meeting necessary listing and regulatory requirements
- Common stock will continue to trade on the OTC market until able to uplist to Nasdaq
Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth
POMPANO BEACH, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading MedTech company focused on the development, manufacture and commercialization of placental-derived biologics, announces the filing of a Form 10 registration statement (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) on September 27, 2024 to register its shares of common stock pursuant to the Securities Exchange Act of 1934, as amended, and reaffirms its strategic decision to pursue a listing on the Nasdaq Stock Market (“Nasdaq”).
Form 10 Filing:
Filing the Registration Statement marks a pivotal step in the Company’s strategy to uplist to Nasdaq. This filing reflects the Company’s ongoing commitment to transparency and strong corporate governance, providing investors with detailed insights into its operations and financial performance. Once the Registration Statement becomes effective 60 days from the filing date, BioStem will be a fully reporting company with the SEC, subject to quarterly, annual and other reporting requirements. BioStem expects that achieving full reporting status will not only enhance the Company’s credibility in the market but will also position The Company for greater visibility and access to capital, ultimately driving shareholder value as it pursues its growth objectives.
Compliance with Nasdaq Listing Requirements:
BioStem's plan to uplist to Nasdaq is contingent upon approval and meeting the necessary listing and regulatory requirements. The company’s common stock will continue to trade on the OTC market under the ticker symbol “BSEM” until BioStem is able to uplist to Nasdaq. BioStem is committed to maximizing shareholder value through listing on a major exchange, and Nasdaq provides a robust and efficient trading platform that offers increased visibility and liquidity opportunities for institutional and retail investors worldwide. In addition to filing the Registration Statement, BioStem recently announced that it has strengthened its compliance and reporting framework as part of the uplisting process by completing two years of audited financial statements.
Jason Matuszewski, CEO of BioStem Technologies, commented: “Our decision to pursue a major exchange listing marks a pivotal development during a period of continued revenue growth. Uplisting to Nasdaq aligns with our strategic initiatives to enhance market visibility, financial transparency and access to capital as we continue to expand through capital markets activities. BioStem is committed to driving revenue growth and market expansion for our products, and we will provide updates on our clinical trials and listing objectives as data becomes available. We look forward to working closely with Nasdaq and updating our stakeholders throughout this process as we pursue our listing objectives.”
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies, Inc. is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. The Company’s quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem placental allograft is processed at the Company's U.S. Federal and Drug Administration (FDA) registered and AATB-accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and Linkedin.
Forward-Looking Statements: Except for statements of historical fact, this press release also contains forward-looking statements. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate", "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this press release include statements regarding the Company’s: (i) ability to meet the listing requirements and successfully uplist to Nasdaq; (ii) ability to boost liquidity opportunities and advance its commercial and clinical initiatives; (iii) ongoing commitment to transparency and strong corporate governance; (iv) ability to promote credibility, increase visibility and access to capital while maximizing shareholder value; (v) growth objectives, including ability to expand through capital market activities, and the impact that may have on the Company’s business and financial condition and (vi) ability to sustain revenue growth and drive market expansion for the Company’s products. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the risk that the Company may be unable to list BSEM’s stock on Nasdaq or maintain compliance with Nasdaq’s continued listing standards; the impact of any changes to the reimbursement levels for the Company's products; the competition that the Company faces, which could adversely affect its business, results of operations and financial condition; rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; the Company’s ability to convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; the risk that the Company may be unable to raise funds to expand its business; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; the Company's ability to maintain production of its products in sufficient quantities to meet demand and the fact that the Company derives a majority of its revenue from one distributor. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
646-863-6893
FAQ
What major step has BioStem Technologies (BSEM) taken towards Nasdaq uplisting?
When will BioStem Technologies (BSEM) become a fully reporting company with the SEC?
What has BioStem Technologies (BSEM) done to strengthen its compliance and reporting framework?
Where does BioStem Technologies' (BSEM) stock currently trade?
